Importance of Patient-Reported Outcomes in the GRIFFIN Study
Rebecca Silbermann, MD, MMS, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study and the importance of individualizing treatment for patients with multiple myeloma.
GRIFFIN Study of Dara-RVd Improves HRQOL in R/R Multiple Myeloma
Rebecca Silbermann, MD, MMS, discusses the findings of the phase 2 GRIFFIN study which were presented at the 2022 ASH Annual Meeting.